Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies

Executive Summary

GSK halts plans for Phase III study of antisense candidate in FAC due to FDA clinical hold for findings of reduced platelet counts in another Phase III trial; Ionis reveals similar findings in Phase III study of another antisense compound.

You may also be interested in...



Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints

Although inotersen met efficacy endpoints in Phase III familial amyloidosis study, adverse event rates raised a red flag and give Alnylam's competing patisiran an edge on safety, at least for now.

Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings

Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.

Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade

Clinical trial failures and holds for drugs derived from nucleic acids from Alnylam and Ionis join those of Dicerna and Genta as the hit rate for these drugs continues to degrade. The real question is whether the failures have been due to a lack of efficacy or safety.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel